ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1834

Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease

Shervin Assassi1, Ning Li 2, Elizabeth Volkmann 3, Maureen Mayes 1, Jun Ying 4, Michael Roth 5, Philip Clements 2, Daniel Furst 6, Dinesh Khanna 7, Jonathan Goldin 2, Robert Elashoff 2 and Donald Tashkin 2, 1Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 2University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, 3University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, 4University of Texas McGovern Medical School at Houston, Houston, TX, 5University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 6University of California, Los Angeles, CA, 7Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: biomarkers and mycophenolate mofetil, interstitial lung disease, Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M097: Systemic Sclerosis & Related Disorder – Clinical II: Cardiopulmonary Involvement (1830–1835)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Response to immunosuppression is highly variable in systemic sclerosis (SSc) related interstitial lung disease (ILD), and there are no widely accepted clinical or biological parameters that predict response to treatment. The interferon (IFN) signature is the most prominent gene expression profile in the peripheral blood cells of SSc patients. We have previously identified 6 serum chemokines that highly correlate with the IFN transcript profile. Herein, we determined whether a composite serum IFN chemokine score has predictive significance for response to immunosuppression in SSc-ILD.

Methods: In the Scleroderma Lung Study (SLS) II (Tashkin et al. Lancet Resp Med. 2016), 142 SSc-ILD patients were randomized to receive either mycophenolate mofetil (MMF) for 2 years or oral cyclophosphamide (CYC) for 1 year followed by 1 year of placebo. The % predicted forced vital capacity (FVC%) was the primary clinical outcome and was measured every 3 months. Baseline serum samples were available in 135 participants. Serum from 45 unaffected controls matched for age, gender, and race in a 1 to 3 ratio to SLS II participants was also investigated. The serum levels of 6 IFN inducible chemokines (IP-10, MIG, MCP-2, B2M, MIP-3 beta, TNFR2) were measured using multiplex assays in a CLIA certified laboratory. A serum IFN composite score was calculated based on the levels of these six chemokines using a previously described method (Bauer et al. Arthritis Rheum. 2009). Similar to the primary outcome analysis in SLS II, a joint model of longitudinal measurements (serially obtained FVC%) and non-ignorable missing data was conducted in order to investigate the predictive significance of the baseline IFN chemokine score for response to treatment.

Results: In this study, 78 (57.8%) participants had diffuse cutaneous disease with a mean baseline FVC% of 66.3%. As shown in Figure 1, the IFN chemokine score was significantly higher in SSc-ILD (fold change= 1.62, p< 0.001) than in controls and decreased significantly in both treatment arms from baseline to 12-months. There was no significant correlation between baseline IFN chemokine score and baseline FVC% (p=0.197). As shown in Table 1, higher baseline IFN chemokine score predicted better response based on higher serial FVC% 3 to 12 months after initiation of treatment in CYC (b=0.91, p=0.009), and MMF (b=0.41, p=0.001) arms, after adjustment for baseline FVC%. In contrast, higher baseline CRP predicted progression of ILD based on significantly lower FVC% after treatment start in the CYC arm (b=-0.56, p< 0.001) and showed a similar trend for lower FVC% 3 to 12 months in the MMF arm (b=-0.15, p=0.091).
Consistent with the different treatment approaches during the second year of SLS II, higher IFN chemokine score at 12 month showed a trend for predicting lower serial FVC% 15-24 months during the placebo treatment period of the CYC arm (b=-0.61, p=0.068) while it continued predicting better response to immunosuppression in the MMF arm (b=0.28, p=0.029).

Conclusion: Higher serum IFN chemokine score in SSc-ILD predicts better response to immunosuppression with MMF and CYC and could be potentially used for identify patients who may derive the most benefit from these two treatments.

Figure 1: Boxplot of Interferon Chemokine Scores by Treatment

Table 1. Predictive Significance of IFN Chemokine Score for Subsequent Serial FVC%s


Disclosure: S. Assassi, Bayer, 2, Boehringer Ingelheim, 2, 5, 8, Integrity Continuing Education, 8, 9, Medscape, 8, 9, Momenta, 2; N. Li, None; E. Volkmann, Boehringer Ingelheim, 5, Boehringer-Ingelheim, 5, Pfizer, 1, 4; M. Mayes, Boehringer Ingelheim, 5, 8, 9, Corbus, 9, Corbus Pharma, 9, Eicos, 9, Eicos Sciences, 9, Galapagos, 5, 9, GlaxoSmithKline, 9, Mitsubishi Tanabe Pharma, 5, Mitsubishi-Tanabe, 5, Reata Pharma, 9, Reata Pharmaceuticals, 9, Sanofi, 9; J. Ying, None; M. Roth, Genentech/Roche, 2; P. Clements, None; D. Furst, Actelion, 2, 5, Actelion Pharmaceuticals, 2, 5, Amgen, 2, 5, BMS, 2, 5, CME, 5, 8, Corbus, 2, 5, Galapagos, 2, 5, Galapogos Novartis, 5, GlaxoSmithKline, 2, GSK, 2, 5, NIH, 2, Novartis, 2, 5, Pfizer, 2, 5, Roche/Genentech, 2, 5, Sanofi, 2, 5; D. Khanna, Acceleron, 5, 8, Acceleron Pharma, 5, Actelion, 5, 8, Actelion Pharmaceuticals, 5, Astra Zeneca, 5, Bayer, 2, 5, 8, Behring, 5, Blade, 5, Blade Therapeutics, 5, 8, Blade therapeutics, 5, BMS, 2, 5, 8, Boehringer Ingelham, 5, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 5, Bristol Myers Squibb, 2, 5, Bristol-Myers Squibb, 2, 5, Celegene, 5, Celgene, 5, 8, ChemomAB, 5, ChemomAb, 5, CiviBioPharma, Inc., 3, Corbus, 5, Corobus, 5, Corpus, 5, CSL Behring, 5, 8, Curizon, 5, Curzion, 5, Cytori, 5, 8, Eicos, 4, Eicos Sciences, 4, Eicos Sciences, Inc, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc, 1, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc., 1, Eicos, Inc, 4, Eicos, Inc., 5, 8, Eicos, INC., 4, Galapagos, 5, Genentech, 5, Genentech/Roche, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 2, 5, Mitsubishi Tanabe Pharma, 5, Mitsubishi Tanabe Pharma Dev America, 5, Mitsubishi Tanabe Pharma Development America, 5, Mitsubishi Tanabi, 5, NIH K24 and R01, 2, NIH / NIAMS K24 AR-063120, 2, NIH/NIAMS R01& K24, 2, Pfizer, 2, 5, Sanofi, 5, Sanofi Aventis, 5, Sanofi-Aventis, 5, 8, Sanofi-Aventis/Genzyme, 5, UCB, 5, UCB Pharma, 5; J. Goldin, None; R. Elashoff, None; D. Tashkin, None.

To cite this abstract in AMA style:

Assassi S, Li N, Volkmann E, Mayes M, Ying J, Roth M, Clements P, Furst D, Khanna D, Goldin J, Elashoff R, Tashkin D. Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/serum-interferon-chemokine-score-predicts-better-response-to-immunosuppression-in-systemic-sclerosis-related-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-interferon-chemokine-score-predicts-better-response-to-immunosuppression-in-systemic-sclerosis-related-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology